2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
The Australian Parkinson’s Mission (APM)
The Australian Parkinson’s Mission (APM) – is an international collaboration between the Garvan Institute, Shake It Up Australia Foundation, Parkinson’s Australia, Cure Parkinson’s and the Michael J. Fox Foundation. The collaboration has been awarded a A$30 million government grant to identify and fast-track better treatments…
The lixisenatide trial
Another trial in the promising diabetes drug cohort for repurposing in Parkinson’s is evaluating the effect of lixisenatide on the progression of Parkinson’s. This trial is co-funded by Cure Parkinson’s and Van Andel Institute through the International Linked Clinical Trials programme. This study is being conducted in France…